Pricing Log in Create free account

Aditxt, Inc. (ADTX) vs Liminatus Pharma Inc. (LIMN)

Aditxt, Inc. and Liminatus Pharma Inc. are both Biotechnology companies. Aditxt, Inc. and Liminatus Pharma Inc. are of similar size ($4.4M and $4.3M). Liminatus Pharma Inc. has the higher net margin (0.00% vs −372,998.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Liminatus Pharma Inc. leads on 6 and Aditxt, Inc. on 5.

Valuation

Metric ADTX LIMN Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B n/m 9.79 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 73.26 n/m 9.21
Earnings yield 0.00% (773.03%) (33.15%)
Free cash flow yield 0.00% (135.00%) (25.50%)

Profitability

Metric ADTX LIMN Biotechnology median
Gross margin 20.28% — 65.16%
Operating margin (128,143.36%) 0.00% 0.00%
Net margin (372,998.60%) 0.00% 0.00%
Free cash flow margin (129,979.72%) 0.00% 0.00%
Return on equity 549.59% 294.43% (56.36%)
Return on assets (236.38%) (471.47%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADTX LIMN Biotechnology median
Revenue growth (TTM) (74.19%) — 6.02%
EPS growth (last fiscal year) (918.27%) (112.19%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ADTX LIMN Biotechnology median
Debt to equity 0.00 4.80 0.00
Current ratio 0.06 1.12 4.72
Net debt to EBITDA 0.18 (0.37) 0.96

Dividend

Metric ADTX LIMN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADTX LIMN Biotechnology median
Market cap 4.39m 4.32m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack